logo
Plus   Neg
Share
Email

Regeneron Pharma: REGN3500 Meets Primary Endpoint In Phase 2 Study

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNYNF,SNY) said the results from a Phase 2 proof-of-concept trial showed that the investigational antibody REGN3500 may provide an alternative targeted approach for patients suffering from asthma. In the trial, REGN3500 monotherapy significantly reduced loss of asthma control and improved lung function compared to placebo.

George Yancopoulos, President and Chief Scientific Officer at Regeneron, said: "We look forward to working with Sanofi to advance REGN3500 through our asthma clinical trial program, as well as continuing our ongoing trials in atopic dermatitis and chronic obstructive pulmonary disease."

REGN3500 was invented using Regeneron's VelocImmune technology, and is being developed jointly by Regeneron and Sanofi as part of a global agreement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ford plans to bring back the Bronco as a dedicated off-road brand when it launches an all-new 4x4 SUV lineup on July 13. The automaker said it will introduce an all-new Bronco brand under the tagline, "Built Wild". The new lineup includes two-door and four-door models of the Bronco as well as the Bronco Sport compact SUV. J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles.
Follow RTT